ArticleThe Journal of general virology2013
Arenavirus reverse genetics for vaccine development.
Article in The Journal of general virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 49 citations in OpenAlex.
- Electroporation- and Liposome-Mediated Co-Transfection of Single and Multiple Plasmids.Pharmaceutics · 2025Article
- A novel BSL-2 Lassa virus reverse genetics system modelling the complete viral life cycle.Emerging microbes & infections · 2024Article
- Plasmid-Based Lassa Virus Reverse Genetics.Methods in molecular biology (Clifton, N.J.) · 2024Article
- S RNA Intergenic Deletions Drive Viral Interference during Arenavirus Infections.bioRxiv : the preprint server for biology · 2023Article
- Article
- Segmented, Negative-Sense RNA Viruses of Humans: Genetic Systems and Experimental Uses of Reporter Strains.Annual review of virology · 2023Review
- Article
- Identification of potent inhibitors of arenavirus and SARS-CoV-2 exoribonucleases by fluorescence polarization assay.Antiviral research · 2022Article
- Article
- Review
- Generation of Bi-Reporter-Expressing Tri-Segmented Arenavirus.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Generation and Characterization of Single-Cycle Infectious Canine Influenza A Virus (sciCIV) and Its Use as Vaccine Platform.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Development of a Simian RNA Polymerase I Promoter-Driven Reverse Genetics for the Rescue of Recombinant Rift Valley Fever Virus from Vero Cells.Journal of virology · 2021Article
- Development of a Recombinant Pichinde Virus-Vectored Vaccine against Turkey Arthritis Reovirus and Its Immunological Response Characterization in Vaccinated Animals.Pathogens (Basel, Switzerland) · 2021Article
- Advances in Development and Application of Influenza Vaccines.Frontiers in immunology · 2021Review
- Reverse genetics approaches for the development of mammarenavirus live-attenuated vaccines.Current opinion in virology · 2020Review
- Development of Reverse Genetics for the Prototype New World Mammarenavirus Tacaribe Virus.Journal of virology · 2020Article
- Rapid Generation of Attenuated Infectious Bursal Disease Virus from Dual-Promoter Plasmids by Reduction of Viral Ribonucleoprotein Activity.Journal of virology · 2020Article
- In vivo rescue of recombinant Zika virus from an infectious cDNA clone and its implications in vaccine development.Scientific reports · 2020Article
- Novel Functions of IFI44L as a Feedback Regulator of Host Antiviral Responses.Journal of virology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Arenaviruses are important human pathogens with no Food and Drug Administration (FDA)-licensed vaccines available and current antiviral therapy being limited to an off-label use of the nucleoside analogue ribavirin of limited prophylactic efficacy. The development of reverse genetics systems represented a major breakthrough in arenavirus research. However, rescue of recombinant arenaviruses using current reverse genetics systems has been restricted to rodent cells. In this study, we describe the rescue of recombinant arenaviruses from human 293T cells and Vero cells, an FDA-approved line for vaccine development. We also describe the generation of novel vectors that mediate synthesis of both negative-sense genome RNA and positive-sense mRNA species of lymphocytic choriomeningitis virus (LCMV) directed by the human RNA polymerases I and II, respectively, within the same plasmid. This approach reduces by half the number of vectors required for arenavirus rescue, which could facilitate virus rescue in cell lines approved for human vaccine production but that cannot be transfected at high efficiencies. We have shown the feasibility of this approach by rescuing both the Old World prototypic arenavirus LCMV and the live-attenuated vaccine Candid#1 strain of the New World arenavirus Junín. Moreover, we show the feasibility of using these novel strategies for efficient rescue of recombinant tri-segmented both LCMV and Candid#1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.